Sitemap
Pages
Posts
Press release
- Tangram Therapeutics Submits Clinical Trial Application for Phase 1/2 Study of TGM-312, a Novel Investigational RNAi MASH Candidate
- Tangram Therapeutics to Participate in Upcoming Investor and Scientific Conferences
- e-therapeutics Relaunches as Tangram Therapeutics and Unveils LLibra OS
- e-therapeutics De-risks Clinical Path for GalOmic Candidate ETX-312 with Positive Non-clinical Data
- e-therapeutics presents new data supporting ETX‑312 as a differentiated, disease-modifying near-clinic GalOmic Treatment for MASH
- e-therapeutics to Present Preclinical Data on ETX-148 at EAHAD 2025
- e-therapeutics Announces Business Updates and Interim Results
- e-therapeutics to Present at Upcoming Scientific Meetings
- Results of Annual General Meeting and Appointment of Jeremy Punnett to the Board of Directors
- e-therapeutics announces completion of £28.90 million fundraise
- Pipeline update and final results for the year ended 31 January 2024
- Lord David Prior Appointed as Chair of e‑therapeutics’ Board of Directors
- Last Day of Dealings on AIM
- Result of General Meeting
- Proposed Fundraise of £28.9m and Cancellation
- Business Update
- Interim Results for the financial year 2023/2024
- Final results for the year ended 31 January 2023
- Filing of four new patent applications
- Successful completion of £13.5 million fundraise
- Interim Results for the financial year 2022/2023
- Filing of eight patent applications on proprietary GalNAc-siRNA technology and target related innovation
- Result of Annual General Meeting
- Director Dealing and Issue of Equity
- Notice of Annual General Meeting and Posting of Annual Report and Accounts
- Final results for the year ended 31 January 2022
- Key Milestone Achieved and Significant Progress on Galapagos Collaboration
- Immuno-Oncology Research Collaboration with iTeos Therapeutics
- Senior Management Update
- RNAi Platform Characterisation Results
- Interim results for six months ended 31 July 2021
- Investor Presentation
- Patent Filing Applications
- Notice of Interim Results
- Commencement of trading on the OTCQX Best Market
- Further milestone in Galapagos collaboration
- Senior Management Appointment and Options Grant
- Results of conditional Fundraise to raise £22.5 million
- Retail Offer
- Final Results for the Year Ended 31 January 2021
- Proposed Fundraise in excess of £20 million
- Notification of Full Year Results Date
- ETX to receive two payments from Galapagos
- Appointment of Chief Financial Officer
- Change of Adviser
- e-therapeutics to present at Shares Investor Evening
- RNA Therapeutics Platform
- COVID-19 Project Update
- Interim Results for six months ended 31 July 2020
- Appointment of Ali Mortazavi as CEO
- Notice of Interim Results
- Expansion of Scientific Advisory Board
- Exercise of Broker Option and Total Fundraise
- Exercise of Broker Option
- Result of Retail Offer
- Retail Offer
- Fundraise of up to £12.4 million
- Collaboration with Galapagos
- Expansion into RNAi and creation of SAB
- COVID-19 update: experimental testing initiated with WuXi AppTec
- e-therapeutics to present at Shares Investor Evening
- Appointment of Chief Business Officer
- Notice of Annual General Meeting and Annual Report
- Anti-viral drug discovery initiative
- Results for the year ended 31 January 2020
- Notification of Full Year Results Date
- Board Changes and Placing
- Half-year Report
- e-therapeutics to work with top pharma company
- Extends Research Collaboration with Novo Nordisk
- Full Year Results
- Notification of Full Year Results Date
- Research Collaboration Agreement with Novo Nordisk
- E-therapeutics and C4X Collaboration
- Drug Discovery Innovation Programme Presentation
- e-therapeutics to present at BioCentury Summit
- Interim Results for six months ended 31 July 2018
- Notice of Interim Results
- Collaboration with C4X Discovery Holdings PLC
- Full Year Results
- Notification of Full Year Results Date
- E-Therapeutics enters two AI collaborations
- Appointment of Director
- Interim Results for the 6 Months Ended 31 July 2017
- Notice of Results
- Edison issues update on e-Therapeutics (ETX)
- Outcome of Strategic Review and Future Plans
- Final Results
- Notification of Full Year Results Date
- New CEO Commences at e-Therapeutics
- Directorate Change
- Appointment of CEO